Get the Stockscreener App
184.32
2.17%
-4.09
Pre-market:
188.83
4.51
+2.45%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $184.32, with a volume of 2.66M.
It is down -2.17% in the last 24 hours and up +101.29% over the past month.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
See More
Previous Close:
$188.41
Open:
$187.61
24h Volume:
2.66M
Relative Volume:
0.42
Market Cap:
$285.75B
Revenue:
$58.07B
Net Income/Loss:
$9.40B
P/E Ratio:
61.21
EPS:
3.0115
Net Cash Flow:
$9.87B
1W Performance:
+92.80%
1M Performance:
+101.29%
6M Performance:
+149.25%
1Y Performance:
+163.84%
1-Day Range:
$183.63
$190.72
1-Week Range:
$92.46
$192.79
52-Week Range:
$61.24
$192.79
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
184.32 | 292.09B | 58.07B | 9.40B | 9.87B | 3.0115 |
|
LLY
Lilly Eli Co
|
1,003.46 | 934.52B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
233.10 | 555.94B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
225.66 | 398.79B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
149.86 | 289.81B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
115.84 | 281.39B | 65.00B | 18.26B | 13.05B | 7.2751 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
Why Astrazeneca (AZN) Dipped More Than Broader Market Today - Yahoo Finance Singapore
AstraZeneca stock soared 103% Monday, holding at high level. Gets rating upgrade. - MSN
AstraZeneca (AZN) Stock Surges Over 100% - GuruFocus
Astrazeneca plc Provides Update on US Regulatory Review of Saphnelo Subcutaneous Administration in Systemic Lupus Erythematosus - marketscreener.com
AstraZeneca (AZN) Faces FDA Setback for Lupus Drug Saphnelo - GuruFocus
Astrazeneca doubles down on China with $15B+ investments - BioWorld MedTech
Jim Cramer Says “I Like AstraZeneca Very Much” - Yahoo Finance
AstraZeneca’s AZD4063 Edges Forward in Rare Genetic Cardiomyopathy Trial: What Investors Should Watch - TipRanks
FDA launches ‘PreCheck’ program; AstraZeneca, Acadia drugs set back - BioPharma Dive
Eyes on Asia: SangeneBio, Newsoara, AstraZeneca - BioXconomy
Global markets live: SpaceX, Tesla, Boeing, PayPal, AstraZeneca… - marketscreener.com
AstraZeneca (AZN) Sees Significant Price Surge of Over 100% - GuruFocus
AstraZeneca's Cancer Therapy Receives FDA Priority Review - Intellectia AI
AstraZeneca (AZN) Seeks FDA Approval for Expanded Cancer Therapy Use - GuruFocus
AstraZeneca provides mixed regulatory updates (AZN:NYSE) - Seeking Alpha
WCM Investment Management LLC Purchases 10,677 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Sold by Principal Financial Group Inc. - MarketBeat
FDA delays but continues review of AstraZeneca (NYSE: AZN) subcutaneous Saphnelo - stocktitan.net
AstraZeneca Responds With Data After FDA Delays Lupus Drug Shot - Benzinga
London's FTSE 100 slips near record level as AstraZeneca falls - marketscreener.com
AstraZeneca (AZN) Gains Priority Review for Datroway in Cancer T - GuruFocus
AstraZeneca Expects FDA Decision on Updated Subcutaneous Saphnelo Application in H1 2026 - marketscreener.com
AstraZeneca (AZN) Faces FDA Setback on Lupus Drug with No Change to Sales Outlook - TipRanks
AstraZeneca PLC (NASDAQ:AZN) Announces Strategic Collaboration Agreement With CSPC Pharmaceuticals - Insider Monkey
FDA Rejects Self-Injected Version of AstraZeneca’s Lupus Drug - Bloomberg
AstraZeneca receives FDA rejection for Saphnelo subcutaneous delivery in lupus patients - MLQ.ai
AstraZeneca Says Breast Cancer Treatment Granted US FDA Priority Review - marketscreener.com
AstraZeneca (AZN) Projected to Post Earnings on Tuesday - MarketBeat
Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S - marketscreener.com
AstraZeneca stock falls after FDA rejects lupus drug injection form By Investing.com - Investing.com India
AstraZeneca stock falls after FDA rejects lupus drug injection form - Investing.com
FDA rejects self-injectable version of AstraZeneca lupus drug - Sharecast News
US FDA rejects AstraZeneca's easier-to-use version of lupus therapy - marketscreener.com
AstraZeneca, Daiichi Sankyo's Breast Cancer Treatment Wins US Priority Review Status - marketscreener.com
US FDA rejects AstraZeneca's application for lupus drug to be given under the skin - marketscreener.com
AstraZeneca Awaits US FDA Decision on Updated Biologics License Application for Lupus Drug - marketscreener.com
AstraZeneca says FDA decision on updated Saphnelo application expected in first half of 2026 - marketscreener.com
AstraZeneca PLCAstraZeneca begins trading on NYSE - Research Tree
US and India reach trade deal, Astrazeneca shares move to NYSE - Yahoo Finance
AstraZeneca (AZN) Stock Soars Over 100% Amid Strong Performance - GuruFocus
AstraZeneca (NASDAQ:AZN) Sets New 12-Month HighShould You Buy? - MarketBeat
AstraZeneca PLC (AZN) Shares Up 105.49% on Feb 2 - GuruFocus
AstraZeneca Shares to Start Trading in US After Listing Upgrade - Bloomberg
AstraZeneca’s Imfinzi recommended for EU approval in early gastric cancer By Investing.com - Investing.com Nigeria
Astrazeneca stock hits all-time high at 190.19 USD By Investing.com - Investing.com India
AstraZeneca begins trading on NYSE - breakingthenews.net
Astrazeneca stock hits all-time high at 190.19 USD - Investing.com
AstraZeneca’s Imfinzi recommended for EU approval in early gastric cancer - Investing.com
Astrazeneca reports GIPR antagonists - BioWorld MedTech
Imfinzi perioperative regimen backed in EU for early gastric cancer at AstraZeneca (AZN) - stocktitan.net
Federated Hermes Inc. Lowers Holdings in AstraZeneca PLC $AZN - MarketBeat
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.18%
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):